Open Access

Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot study

  • Authors:
    • Jan Kučera
    • Karolína Strnadová
    • Barbora Dvořánková
    • Lukáš Lacina
    • Ivana Krajsová
    • Jiří Štork
    • Hana Kovářová
    • Helena Kupcová Skalníková
    • Petr Vodička
    • Jan Motlík
    • Pavel Dundr
    • Karel Smetana
    • Ondřej Kodet
  • View Affiliations

  • Published online on: September 17, 2019     https://doi.org/10.3892/or.2019.7319
  • Pages: 1793-1804
  • Copyright: © Kučera et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The steadily increasing incidence of malignant melanoma (MM) and its aggressive behaviour makes this tumour an attractive cancer research topic. The tumour microenvironment is being increasingly recognised as a key factor in cancer biology, with an impact on proliferation, invasion, angiogenesis and metastatic spread, as well as acquired therapy resistance. Multiple bioactive molecules playing cooperative roles promote the chronic inflammatory milieu in tumours, making inflammation a hallmark of cancer. This specific inflammatory setting is evident in the affected tissue. However, certain mediators can leak into the systemic circulation and affect the whole organism. The present study analysed the complex inflammatory response in the sera of patients with MM of various stages. Multiplexed proteomic analysis (Luminex Corporation) of 31 serum proteins was employed. These targets were observed in immunohistochemical profiles of primary tumours from the same patients. Furthermore, these proteins were analysed in MM cell lines and the principal cell population of the melanoma microenvironment, cancer‑associated fibroblasts. Growth factors such as hepatocyte growth factor, granulocyte‑colony stimulating factor and vascular endothelial growth factor, chemokines RANTES and interleukin (IL)‑8, and cytokines IL‑6, interferon‑α and IL‑1 receptor antagonist significantly differed in these patients compared with the healthy controls. Taken together, the results presented here depict the inflammatory landscape that is altered in melanoma patients, and highlight potentially relevant targets for therapy improvement.
View Figures
View References

Related Articles

Journal Cover

November-2019
Volume 42 Issue 5

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Kučera J, Strnadová K, Dvořánková B, Lacina L, Krajsová I, Štork J, Kovářová H, Skalníková HK, Vodička P, Motlík J, Motlík J, et al: Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot study. Oncol Rep 42: 1793-1804, 2019
APA
Kučera, J., Strnadová, K., Dvořánková, B., Lacina, L., Krajsová, I., Štork, J. ... Kodet, O. (2019). Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot study. Oncology Reports, 42, 1793-1804. https://doi.org/10.3892/or.2019.7319
MLA
Kučera, J., Strnadová, K., Dvořánková, B., Lacina, L., Krajsová, I., Štork, J., Kovářová, H., Skalníková, H. K., Vodička, P., Motlík, J., Dundr, P., Smetana, K., Kodet, O."Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot study". Oncology Reports 42.5 (2019): 1793-1804.
Chicago
Kučera, J., Strnadová, K., Dvořánková, B., Lacina, L., Krajsová, I., Štork, J., Kovářová, H., Skalníková, H. K., Vodička, P., Motlík, J., Dundr, P., Smetana, K., Kodet, O."Serum proteomic analysis of melanoma patients with immunohistochemical profiling of primary melanomas and cultured cells: Pilot study". Oncology Reports 42, no. 5 (2019): 1793-1804. https://doi.org/10.3892/or.2019.7319